+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Cost-effectiveness of salmeterol/fluticasone combination therapy vs. fluticasone propionate in Japanese asthmatic patients



Cost-effectiveness of salmeterol/fluticasone combination therapy vs. fluticasone propionate in Japanese asthmatic patients



Yakugaku Zasshi 130(4): 593-603



We commenced to estimate the economic impact of salmeterol/fluticasone combination (SFC) therapy compared to fluticasone propionate (FP) therapy for asthma control in Japanese patients. A Markov model with five health states, developed by Price in 2002, was used. 1-week transition probabilities among status of asthma management were obtained from literature and epidemiological data from public data base. Direct cost for treatment was estimated from Japan medical fee schedule. Cost and effectiveness were not discounted due to 12-week simulation by the model. Univariate sensitivity analyses were undertaken to examine the main variables affecting cost-effectiveness. Probabilistic analysis was also undertaken to discuss statistical argument and to provide information for decision-making. In this analysis, the model was run over a 12-week period of time using transition probabilities. The results showed that treatment with SFC resulted in a higher proportion of totally controlled weeks per patient than treatment with FP (65.0 vs. 49.5%; incremental effectiveness by 15.5%), and lower mean direct asthma management costs ( yen168 702 vs. yen227 820). Probabilistic sensitivity analysis, conducted to assess robustness of the above base case result, showed that in the 95% of cases SFC was dominant (more effective and less costly) to FP. It suggested that SFC will be the most cost-effective therapy for asthma control. It would, however, be required to further evaluate cost-effectiveness of SFC in long-term observation.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 052371027

Download citation: RISBibTeXText

PMID: 20372007

DOI: 10.1248/yakushi.130.593


Related references

Cost-Effectiveness Analyses of Salmeterol/Fluticasone Propionate Combination Product and Fluticasone Propionate in Patients with Asthma II: Study Methodologies. Pharmacoeconomics 16(2 Suppl.): 9-14, 1999

Cost-Effectiveness Analyses of Salmeterol/Fluticasone Propionate Combination Product and Fluticasone Propionate in Patients with Asthma I: Introduction and Overview. Pharmacoeconomics 16(2 Suppl.): 1-8, 1999

Salmeterol/fluticasone propionate combination product in asthma. An evaluation of its cost effectiveness vs fluticasone propionate. Pharmacoeconomics 16(Suppl. 2): I-Viii, 1-34, 2000

Initiating or changing to a fixed-dose combination of Fluticasone propionate/Formoterol over Fluticasone propionate/Salmeterol: A real-life effectiveness and cost impact evaluation. Respiratory Medicine 129: 199-206, 2017

Stepping down to fluticasone propionate or a lower dose of fluticasone propionate/salmeterol combination in asthma patients recently initiating combination therapy. Allergy and Asthma Proceedings 31(3): 203-210, 2011

Cost-effectiveness of combination fluticasone propionate-salmeterol 250/50 microg versus salmeterol in severe COPD patients. International Journal of Chronic Obstructive Pulmonary Disease 5: 179-187, 2010

The salmeterol/fluticasone propionate dry powder combination Diskus has a faster onset of effect compared with salmeterol or fluticasone propionate in patients with asthma. Journal of Allergy & Clinical Immunology 103(1 Part 2): S132, 1999

Fluticasone propionate/salmeterol diskus combination product provides superior asthma control compared with fluticasone propionate and salmeterol alone in patients previously receiving PRN short-acting beta2-agonists alone. Journal of Allergy & Clinical Immunology 109(1 Suppl.): S245, 2002

Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma. Pharmacoeconomics 22(12): 815-825, 2004

First-line therapy with fluticasone propionate/salmeterol combination product provides superior asthma control versus montelukast or fluticasone propionate alone. Journal of Allergy & Clinical Immunology 109(1 Suppl.): S252, 2002

P177 Fluticasone propionate/formoterol fumarate combination therapy is as effective as fluticasone propionate/salmeterol xinafoate in the treatment of asthma: a randomised controlled trial. Thorax 65(Suppl 4): A152-A153, 2010

Comparative efficacy of combination of fluticasone and salmeterol; fluticasone, salmeterol and montelukast; fluticasone, salmeterol, and levocetirizine in moderate persistent asthma: A study of 120 patients. Chest 132(4): 512a-1, 2007

Evaluation of fluticasone propionate and fluticasone propionate/salmeterol combination on exercise in pediatric and adolescent patients with asthma. Open Respiratory Medicine Journal 5: 11-18, 2011

Step-down therapy in well-controlled asthmatic patients using salmeterol xinafoate/fluticasone propionate combination therapy. Journal of Asthma and Allergy 9: 65-70, 2016

Initiation of maintenance therapy with salmeterol/fluticasone propionate combination therapy in moderate asthma: a comparison with fluticasone propionate. Journal of Asthma 44(6): 437-441, 2007